The DOI matches its Crossref record; 236 of the 236 references it cites were found in a registry or an index.
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
Open accessAbstract
Background: Breast cancer is associated with a relatively good prognosis. Prognostic factors examined to date are related to early recurrence while those related to late recurrence and their countermeasures remain unclear. Therefore, we examined the factors related to late recurrence. Patients and Methods: From January 1980 to August 2012, 4,774 patients who underwent primary treatment and estrogen (ER) and progesterone receptor (PgR) assessment were enrolled in this study. The patients were divided into two groups, those with a follow-up period <10 years and those without any recurrence at 10 years but who continued follow-up examinations. Recurrence occurred in 711 patients followed up for <10 years and in 51 patients for ≥10 years. Results: The overall 10-year cumulative disease-free survival rate was 79.5%, and the recurrence rate at ≥10 years was 5.8%. A multivariate analysis revealed that the factors related to late recurrence were PgR positivity and positive nodes. This result differed from that for early recurrence in terms of ER/PgR, Ki-67 index and p53 overexpression. Conclusion: PgR positivity and lymph node metastases significantly correlated with late recurrence. Therefore, it is important to evaluate appropriate measures such as treatment period and treatment regimen for hormone-sensitive patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–236 of 236
Anderson, W. F., Chen, B. E., Jatoi, I., & Rosenberg, P. S. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9231-y · Cited by 90
Platet, N., Prévostel, C., Derocq, D., BRESSION, D., Rochefort, H., & Garcia, M. (1998) · International Journal of Cancer · Cited by 78
Estrogen and progesterone receptor concordance between primary and recurrent breast cancer
Li, B. D. �., Byskosh, A., Duda, R. B., & Molteni, A. (1994) · Journal of Surgical Oncology · doi:10.1002/jso.2930570202 · Cited by 74
Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients
André, F., Berrada, N., & Desmedt, C. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833fb384 · Cited by 74
Fuentes, G., Scaltriti, M., Baselga, J. M., & Verma, C. S. (2011) · Breast Cancer Research · doi:10.1186/bcr2888 · Cited by 74
Peto, R. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.79 · Cited by 73
Amenorrhea from Breast Cancer Therapy — Not a Matter of Dose
Swain, S. M., Jeong, J., & Wolmark, N. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1009616 · Cited by 72
Five Years of Tamoxifen--or More?
Peto, R. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.24.1791 · Cited by 69
Berns, E., Klijn, J. G. M., van Putten, W. L., de Witte, H. H., Look, M. P., Gelder, M. E. M., Willman, K., Portengen, H., Benraad, T. J., & Foekens, J. A. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.121 · Cited by 69
Becker, S., Becker‐Pergola, G., Wallwiener, D. R., Solomayer, E., & Fehm, T. N. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9095-6 · Cited by 68
Molino, A., Micciolo, R., Turazza, M., Bonetti, F., Piubello, Q., Corgnati, A., Sperotto, L., Recaldin, E., Spagnolli, R., Manfrin, E., et al. (1997) · Breast Cancer Research and Treatment · doi:10.1023/a:1005769925670 · Cited by 66
Guetta, V., Lush, R. M., Figg, W. D., et al. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80302-6 · Cited by 64
Mitochondrial HEP27 Is a c-Myb Target Gene That Inhibits Mdm2 and Stabilizes p53
Deisenroth, C., Thorner, A. R., Enomoto, T., Perou, C. M., & Zhang, Y. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01284-09 · Cited by 64
de Haes, J. C. J. M., Olschewski, M., Kaufmann, M., Schumacher, M. C., Jonat, W., & Sauerbrei, W. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.064 · Cited by 62
Letrozole in the extended adjuvant setting: MA.17
Goss, P. E. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9698-1 · Cited by 60
Khoshnoud, M. R., Löfdahl, B., Fohlin, H., Fornander, T., Stål, O., Skoog, L. K., Bergh, J. C. S., & Nordenskjöld, B. A. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1202-7 · Cited by 59
Is gene array testing to be considered routine now?
Paik, S. (2011) · The Breast · doi:10.1016/s0960-9776(11)70301-0 · Cited by 55
Solomayer, E., Diel, I., Salanti, G., Hahn, M., Gollan, C., Schütz, F., & Bastert, G. (2001) · PubMed · Cited by 50
Zheng, W., Lu, J., Zheng, J., Hu, F.-X., & Ni, C.-R. (2001) · Steroids · doi:10.1016/s0039-128x(01)00121-0 · Cited by 49
Fehm, T. N., Banys, Hartkopf, Krawczyk, Meier-Stiegen, Neubauer, H. J., & Kaiser (2012) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s26431 · Cited by 48
Bevacizumab for Advanced Breast Cancer: All Tied Up With a RIBBON?
Burstein, H. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2684 · Cited by 48
Adjuvant tamoxifen in postmenopausal breast cancer: Preliminary results of a randomized trial
Delozier, T., Julien, J., Juret, P., et al. (1986) · Breast Cancer Research and Treatment · doi:10.1007/bf01806795 · Cited by 46
Bramwell, V. H. C., Pritchard, K. I., Tu, D., Tonkin, K. S., Vachhrajani, H., Vandenberg, T. A., Robert, J., Arnold, A., OʼReilly, S., Graham, B., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp326 · Cited by 37
Lara, M. F., García‐Escudero, R., Ruiz, S., Santos, M., Moral, M., Martínez‐Cruz, A. B., Segrelles, C., Lorz, C., & Paramio, J. M. (2007) · Molecular Carcinogenesis · doi:10.1002/mc.20376 · Cited by 34
Namer, M., Fargeot, P., Roche, H. H., Campone, M., Kerbrat, P., Romestaing, P., Monnier, A., Luporsi, É., Montcuquet, P., & Bonneterre, J. M. (2005) · Annals of Oncology · doi:10.1093/annonc/mdj022 · Cited by 33
Earl, H., Gray, R. G., Kerr, D. J., et al. (1997) · Clinical Oncology · doi:10.1016/s0936-6555(97)80067-2 · Cited by 31
Preventing Relapse Beyond 5 Years: The MA.17 Extended Adjuvant Trial
Goss, P. E. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.03.025 · Cited by 29
Tamoxifen: the Long and Short of It
Swain, S. M. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.21.1516 · Cited by 25
Piccart, M. J., Parker, L. M., & Pritchard, K. I. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg290 · Cited by 23
Variation in use of adjuvant tamoxifen
Davies, C., McGale, P., Pető, R., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78869-3 · Cited by 18
Morales, L., Canney, P. A., Dyczka, J., Rutgers, E. J. T., Coleman, R. E., Čufer, T., Wełnicka-Jaśkiewicz, M., Nortier, J. W. R., Bogaerts, J., Therasse, P., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.10.009 · Cited by 18
Kaufmann, M., Graf, E., Jonat, W., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3433 · Cited by 17
Taktak, A. F. G., Eleuteri, A., Lake, S. P., & Fisher, A. C. (2008) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2008.04.005 · Cited by 12
Tamoxifen for early breast cancer: Better late than never
Gray, R. G., Davies, C., & Perry, P. (2000) · Annals of Oncology · doi:10.1023/a:1008323116265 · Cited by 5
Pm, M., Romain, S., Spyratos, F., et al. (1991) · PubMed · Cited by 4
Research works printed but not linked: 3
- 10.1007/s10147-006-0601-6 · doi:10.1007/s10147-006-0601-6
- 10.1186/1477-7819-9-131 · doi:10.1186/1477-7819-9-131
- 10.1186/bcr2143 · doi:10.1186/bcr2143
Cited by
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
Chandrashekar, D. S., Bashel, B., Balasubramanya, S. A. H., Creighton, C. J., Ponce-Rodriguez, I., Chakravarthi, B. V. S. K., & Varambally, S. (2017) · Neoplasia · doi:10.1016/j.neo.2017.05.002 · Cited by 6,086
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Metadata
- Authors
- Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N.
- Venue
- Oncology
- Publisher
- S. Karger AG
- Published
- 2013
- Volume
- 85
- Issue
- 2
- Pages
- 100-110
- ISSN
- 0030-2414 (ISSN-L)
- 1423-0232
- OpenAlex
- W2044702943
- Cited by
- 13,166
- References
- 236
- FWCI
- 323.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- creativecommons.org/licenses/by-nc/3.0/ (vor)
- creativecommons.org/licenses/by-nc/3.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.